california dmhc glp-1 coverage exclusion allowed 🚨 Alert: for Obesity Medications at Risk Just two years after Medi-Cal began covering FDA-approved medications for obesity, that coverage is set to end in January 2026 — a Governor's 2025-26 May Revision Proposes

For some people, this can lead to: Feeling overly full after small meals Nausea or vomiting Bloating and gas Changes in bowel habits, including diarrhea or constipation Another important piece of the puzzle is fermentation

Only one study showed no residual gastric contents in all patients taking GLP-1 receptor agonists after having the patients fast from solids for 24 hours and from liquids for 12 hours (n=57)

NAFLD and NASH currently have no approved treatments though they impact 25% and 5% of U.S

If you regain more than 5% of your target weight, its a sign that the taper may need adjustment, or in some cases, a temporary return to the medication

Now, regulators are revisiting those requirements after concerns that the stricter standards could force sterilization facilities, especially smaller operators, out of the market and disrupt the supply of critical medical devices